Drug Profile
Cipaglucosidase alfa - Amicus Therapeutics
Alternative Names: AT B200; cipaglucosidase alfa-atga; Pombiliti; Recombinant-human-acid-alpha-glucosidase-enzyme-Amicus; rhGAA-AmicusLatest Information Update: 06 Mar 2024
Price :
$50
*
At a glance
- Originator Amicus Therapeutics
- Class Alpha-glucosidases; Enzymes
- Mechanism of Action Alpha glucosidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Glycogen storage disease type II
Most Recent Events
- 31 Dec 2023 Cipaglucosidase alfa - Amicus Therapeutics receives Orphan Drug status for Glycogen storage disease type II in United Kingdom, prior to December 2023
- 28 Sep 2023 POMBILITI (cipaglucosidase alfa-atga) has a boxed warning for hypersensitivity reactions, infusion-associated reactions and risk of acute cardiorespiratory failure
- 28 Sep 2023 Registered for Glycogen storage disease type II (Combination therapy) in USA (IV)